10:03 AM EDT, 06/05/2024 (MT Newswires) -- AbbVie ( ABBV ) said Wednesday it has treated the first patient in a phase 3 clinical trial assessing ABBV-383 as a potential treatment for multiple myeloma, a blood cancer characterized by abnormal plasma cell proliferation.

The study will evaluate the drug candidates' efficacy, safety, and tolerability relative to standard available therapies in patients with relapsed or refractory multiple myeloma who have received at least two lines of previous therapy, the company said.

Price: 164.96, Change: +2.82, Percent Change: +1.74